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Pelizaeus-Merzbacher- Disease (PMD) is a neurodegenerative disease that causes 
neurodevelopmental delay and hypotonicity in infancy. It is an X-linked myelin 
synthesis disorder. Symptoms initially begin before 3 months of age and gradually 
neurological manifestation such as seizure and optic atrophy appear. There is 
diffuse white matter involvement (dysmyelination) in the brain MRI.
PelizaeusMerzbacher disease (PMD) is a progressive disorder in myelin formation 
which is transmitted with an X-linked pattern of inheritance. This disease was first 
described in 1885 by Pelizaeus and in 1910 by Merzbacher. In 1964, Zeman and 
colleagues explained the role of proteolipid protein (PLP1) in the disease. The 
gene of PMD is located on the long arm of the X chromosome (Xq21.2q-22). 
Dysmyelination is the major pathologic defect in this disease. The brain MRI 
pattern is highly remarkable.
It shows arrest of myelination in the stage that the brain should be myelinated. 
The clinical severity is related to the pattern of myelinated white matter. The T1 
weighted images show low intensity of all unmyelinated white matter structures; 
whereas, these structures show high signal intensity in T2 weighted. Mutation in 
PLP1 that encodes the essential intrinsic membrane protein of CNS myelin is the 
main cause of PMD.
Severe form of the disease is presented with severe hypotonia at birth. These 
patients have stridor and feeding difficulties and their symptoms are very similar 
to spinal muscular atrophy (SMA) without any involvement in anterior horn cells. 
Spastic paraplegia type 2 (X-linked type of spastic paraplegia) is an allelic variant 
of PMD with PLP gene defect that presents with spasticity in the lower extremities 
and they have slow progression in their disease.
Pelizaeus-Merzbacher-like disease (PMLD) is a hypomyelinating 
leukoencephalopathy disorder with a genetically heterogeneous pattern. Mutations 
in the GJA12/GJC2 gene can cause one form of autosomal recessive pattern of 
Pelizaeus-Merzbacher-like disease.
Pelizaeus-Merzbacher-like disease (PMLD) is clinically similar to PMD and 
includesny stagmus, ataxia and hypotonicity followed by spasticity but mutation of 
the PLP1 gene is not detected. In most patients, no gene has been identified, but in 
a small group of them (less than 10%) mutation in GJC2 (so called GJA12) codon 
for Connexin 46.6 (Cx47) has been detected.
This gene is called GJA12 and encodes the gap junction protein 12. Mutation of 
the gap junction of protein alpha 12 causes one of the autosomal recessive types of 
PMLD.
Diagnosis is performed by sequencing the entire coding region of GJC2. This assay 
will detect point mutation, small deletion and small insertion. In this type of PMLD, 
9
Iran J Child Neurol. 2014 Autumn Vol 8 No 4  Suppl. 1
MRI shows diffuse white matter involvement and basal 
ganglia calcification.
On the other hand, some of PMLD cases are 
transmittedby an X-linked pattern. Gene locus is located 
on the outerpart of the PLP gene location on the X 
chromosome. 
Orthmann and his colleagues reported a form of PMLD 
in a Turkish family (in 2004) that was transmitted by 
anautosomal recessive pattern .These patients had 
nystagmus, developmental delay, ataxia, dystonia, 
dysarthria and progressive spasticity. Their clinical 
manifestations were presented in early infancy. 
TEMG-NCV also showed mild peripheral sensory 
and motor neuropathy. Five different mutations in 
GJA12 gene were detected in these patients. Bugiani 
reported eight members of a Saudi Arabia family with 
PMLD. Brain MRI of these patients showed diffuse 
white matter involvement.
Were ported a new mutation of Pelizaeus-Merzbacher-
Like Disease, first report from Iran, (a homozygote 
deletion as c902-918Del)in a 10-month-old girl from 
healthy second cousin parents that had not beenreported 
in previous studies. Her clinical manifestations were 
nystagmus, psychomotor delay, hypotonicity, head 
nodding and dysmyelination.
(New Mutation of Pelizaeus - Merzbacher - Like 
Disease; A Report from Iran, ParvanehKarimzadeh, 
FarzadAhmadabadi, OmidAryani, MassoudHoushmand, 
Alireza Khatami, Iran J Radiol. 2014 May; 11(2): e6913).
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